Trial Profile
A Phase 2, Study of Apalutamide and Abiraterone Acetate in Castration-Resistant Bone Metastatic Prostate Cancer Patients Evaluating a Predetermined Biomarker Signature
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 28 Feb 2024
Price :
$35
*
At a glance
- Drugs Abiraterone acetate (Primary) ; Apalutamide (Primary) ; Prednisone
- Indications Adenocarcinoma; Bone metastases; Prostate cancer
- Focus Therapeutic Use
- 22 Feb 2024 Planned End Date changed from 30 Apr 2024 to 30 Apr 2025.
- 22 Feb 2024 Planned primary completion date changed from 30 Apr 2024 to 30 Apr 2025.
- 01 Sep 2023 Status changed from suspended to active, no longer recruiting.